Sol-Gel Technologies (SLGL) Profit After Tax (QoQ) (2018 - 2026)

Sol-Gel Technologies (SLGL) Profit After Tax (QoQ) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Sol-Gel Technologies 226.64 Mn 216.50 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 100.00%
Dec 31, 2025 -150.27%
Sep 30, 2025 -48.82%
Jun 30, 2025 362,812,400.00%
Mar 31, 2025 100.00%
Dec 31, 2024 -4,084.15%
Sep 30, 2024 -118.52%
Jun 30, 2024 85,912,943.48%
Mar 31, 2024 100.00%
Dec 31, 2023 15.32%
Sep 30, 2023 -195.66%
Jun 30, 2023 1,388,371,993.02%
Mar 31, 2023 100.00%
Dec 31, 2022 -9,948,666,300.00%
Sep 30, 2022 -1,600.00%
Jun 30, 2022 -95.83%
Mar 31, 2022 -100.00%
Dec 31, 2021 991.06%
Sep 30, 2021 367,428,471.43%
Jun 30, 2021 94.44%